Heron Therapeutics (AXD2) Q2 2026 Earnings Report

The call showed meaningful commercial strengths — notably strong year-over-year growth in the acute care franchise, particularly APONVIE and ZYNRELEF, improved adjusted EBITDA, and proactive balance sheet and legal actions. However, the June court decision creating potential generic competition for CINVANTI (the company's largest product), the subsequent withdrawal of full-year guidance, reduced pro forma cash after required principal payments, an increased GAAP net loss, and a pause in sales force expansion introduce significant near-term uncertainty. Overall, positive operating pockets are overshadowed by material legal, cash and guidance risks.

Heron withdrew its full‑year 2026 guidance of $173–$183 million in net product sales and $10–$20 million in adjusted EBITDA, citing three uncertainties (the June court decision affecting potential generic timing/terms for CINVANTI, the pause of a planned second‑half sales‑force expansion and tightened spending, and consideration of strategic alternatives) and will instead report quarterly on cash, spending and covenant compliance; at quarter end it had $42.7 million in cash, equivalents and short‑term investments (pro forma ~$28.5M after a $13.5M principal paydown and ~ $24.3M if a further $4.0M payment is made by Sept. 15), agreed an amended Hercules facility that waives June covenants and resets monthly minimum revenue and EBITDA covenants plus a minimum cash covenant through December 2027, and reported Q2 results of $37.7M net revenues, 69.3% gross margin, $2.0M operating loss, $5.5M net loss and $3.2M adjusted EBITDA.